Saltar al contenido
Merck

Documentos clave

Ver Toda la documentación

569396

Staurosporine

from Streptomyces sp., ≥97% (HPLC), liquid, protein kinase inhibitor, Calbiochem

Sinónimos:

InSolution Staurosporine, Streptomyces sp., PKA Inhibitor II, MLCK Inhibitor I

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C28H26N4O3
Número CAS:
62996-74-1
Peso molecular:
466.53
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD00077402
Assay:
≥97% (HPLC)
Form:
liquid
Quality level:
100
Storage condition:
OK to freeze, protect from light
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Staurosporine, Streptomyces sp., InSolution, ≥97%, 1 mM solution, protein kinase inhibitor

Quality Level

100

assay

≥97% (HPLC)

form

liquid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

shipped in

wet ice

storage temp.

−70°C

SMILES string

[n]21c3c4[n](c6c(c4c7c(c3c8c2cccc8)CNC7=O)cccc6)[C@@H]5O[C@]1([C@@H]([C@@H](C5)NC)OC)C

InChI

1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1

InChI key

HKSZLNNOFSGOKW-FYTWVXJKSA-N

General description

A potent, cell-permeable broad spectrum inhibitor of protein kinases. Inhibits CaM kinase (IC50 = 20 nM), myosin light chain kinase (IC50 = 1.3 nM), protein kinase A (IC50 = 7 nM), protein kinase C (IC50 = 0.7 nM), and protein kinase G (IC50 = 8.5 nM). Also inhibits platelet aggregation induced by collagen or ADP but has no effect on thrombin-induced platelet aggregation. Induces apoptosis in human malignant glioma cell lines. Arrests normal cells at the G1 checkpoint.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
PKA
Product competes with ATP.
Reversible: yes
Target IC50: 7 nM, 20 nM, 1.3 nM, 700 pM, 8.5 nM, against protein kinase A , CaM kinase, myosin light chain kinase, protein kinase C, and protein kinase G, respectively

Packaging

Packaged under inert gas

Physical form

A 1 mM (100 µg/214 µl) solution of Staurosporine (Cat. No. 569397) in DMSO.

Preparation Note

Following initial thaw, aliquot, purge with inert gas, and freeze (-70°C).

Other Notes

Couldwell, W.T., et al. 1994. FEBS Lett.345, 43.
Nishimura, H. and Simpson, I.A. 1994. Biochem. J.302, 271.
Bruno, S., et al. 1992. Cancer Res.52, 470.
Kiss, Z. and Deli, E. 1992. Biochem. J.288, 853.
Vitale, M.L., et al. 1992. Neuroscience51, 463.
Hoffman, R. and Newland, E.S. 1991. Cancer Chemotherap. Pharmacol.28, 102.
Oka, S., et al. 1986. Agric. Biol. Chem.50, 2723.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Irritant (B)

Still not finding the right product?

Explore all of our products under

Clase de almacenamiento

10 - Combustible liquids

wgk

WGK 1

flash_point_f

188.6 °F - closed cup - (Dimethylsulfoxide)

flash_point_c

87 °C - closed cup - (Dimethylsulfoxide)

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Athena Kyrkou et al.
Nature communications, 15(1), 5115-5115 (2024-06-16)
Neurofibromatosis Type II (NFII) is a genetic condition caused by loss of the NF2 gene, resulting in activation of the YAP/TAZ pathway and recurrent Schwann cell tumors, as well as meningiomas and ependymomas. Unfortunately, few pharmacological options are available for
Shuai Guo et al.
British journal of pharmacology, 179(21), 4974-4991 (2022-07-15)
Macrophage-rich atherosclerotic arteries are highly active in glycolysis. PFKFB3, a key glycolytic enzyme, has emerged as a potential therapeutic target in atherosclerosis. Small-molecule inhibitors of PFKFB3, such as 3PO and PFK158, have demonstrated efficacy in hampering atherogenesis in preclinical models.
Erin R Spiller et al.
Frontiers in oncology, 11, 771173-771173 (2022-01-08)
Three-quarters of compounds that enter clinical trials fail to make it to market due to safety or efficacy concerns. This statistic strongly suggests a need for better screening methods that result in improved translatability of compounds during the preclinical testing
Ver todos los artículos relacionados